Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

Clinical trial NCT03809624 · TERMINATED

Trial details

NCT number: NCT03809624
Sponsor: Inhibrx Biosciences, Inc
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Metastatic Solid Tumors Non-small Cell Lung Cancer Melanoma Head and Neck Squamous Cell Carcinoma Gastric Adenocarcinoma Renal Cell Carcinoma Esophageal Adenocarcinoma Nasopharyngeal Carcinoma Oropharyngeal Carcinoma

Start date: 2019-01-30
Primary completion: 2024-10-03
Enrollment: 160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.